Transition From Alendronate to Romosozumab (AMG 785)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated with alendronate.
Epistemonikos ID: 40aece6e82c734ebe21ceb51622d3425372bcb25
First added on: May 10, 2024